The COVID19 pandemic {#s1}
====================

The COVID-19 (Coronavirus Disease 2019) pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infecting one million and killing more than 50\'000 people worldwide as of April 2, has fueled enormous interest in the mechanisms whereby this new coronavirus causes acute respiratory distress syndrome (ARDS) and multiorgan failure. The estimated 79% infection rate from undocumented cases in COVID-19 patients ([@bib24]), and the high lethality of the infections, along with its enormous socio-economic impact, emphasize the importance of fully understanding these mechanisms for developing effective treatment strategies.

Early in 2020 reports of the full RNA sequence of the SARS-CoV-2 virus highlighted its remarkable similarity with the SARS-CoV virus, which was responsible for a global outbreak that killed 774 people in 2003 ([@bib36]; [@bib42]). As the processes whereby the SARS-CoV virus infects the lung cells had been already identified ([@bib21]), and it was held that SARS-CoV-2 uses identical mechanisms, these discoveries allowed an unprecedented acceleration of knowledge.

Why and how does SARS-CoV-2 infect the lungs? {#s2}
=============================================

Since 2005, it was known that SARS-CoV uses the angiotensin converting enzyme (ACE)−2 as its receptor to infect cells. ACE-2 is highly expressed in the vascular endothelium ([@bib21]) and also in the lungs, particularly in endothelial and type 2 alveolar epithelial cells ([@bib10]). The resemblances of SARS-CoV and SARS-CoV-2 include a 76.5% homology in the amino acid sequence of the spike (S) protein of the envelope that both viruses use to infect mammalian cells. With a 4 amino acid residue difference the SARS-CoV and the SARS-CoV-2 S protein share an almost identical 3-D structure of the receptor binding domain ([@bib36]) and, moreover, binds to ACE-2 with even higher affinity than SARS-CoV ([@bib35]), which may explain its virulence and predilection for the lungs.

Upon binding to ACE-2, both SARS-CoV and SARS-CoV-2 activate the transmembrane serine protease-2 (TMPRSS2), which is highly expressed in the lungs. Through fusion of its envelope with the cell membrane, the virus penetrates into the cells ([Figure 1](#fig1){ref-type="fig"}, panel A) ([@bib12]; [@bib13]). Of note, SARS-CoV-2 entry can be prevented by SARS convalescent sera containing neutralizing antibodies, or by TMPRSS2 inhibitors such as camostat ([@bib13]) and nafamostat mesylate, both approved in Japan for clinical use for other indications ([@bib37]). These seminal discoveries suggested several potential therapeutic strategies to prevent SARS-CoV-2 entry into pulmonary cells ([@bib40]) ([Figure 1](#fig1){ref-type="fig"}, panel A).

What is the role of ACE-1 and ACE-2 in infections caused by SARS-CoV and SARS-CoV-2? {#s3}
====================================================================================

Are there similarities between ACE-1, the target of ACEIs, and ACE-2, the target of SARS-CoV and SARS-CoV-2? This is obviously the essential question for physicians using ACEIs or angiotensin-receptor blockers (ARBs), which are frequently prescribed in a multitude of patients.

Both ACE-1 and ACE-2 cleave angiotensin peptides ([Figure 1](#fig1){ref-type="fig"}, panel B). However, they differ markedly: ACE-1 cleaves the dipeptide His-Leu from angiotensin I, thus generating angiotensin (Ang) II, which causes vaso- and broncho-constriction, increases vascular permeability, inflammation, and fibrosis and thereby promotes the development of ARDS and lung failure in patients infected with the SARS-CoV and SARS-CoV-2 ([@bib39]) ([Figure 1](#fig1){ref-type="fig"}, panel B).

Compelling evidence from animal models of ARDS, lung fibrosis, asthma, and chronic obstructive lung disease indicate that these effects are essential for ARDS to develop and that both ACEIs and ARBs block the disease-propagating effect of Ang II ([@bib6]; [@bib14]; [@bib18]).

ACE-2, which is expressed more abundantly on the apical than the basolateral side of polarized alveolar epithelial cells ([@bib17]), shares only 42% amino acid sequence homology with ACE-1 ([@bib11]). It cleaves only one amino acid residue (Leu or Phe) from Ang I and Ang II, respectively, to generate Ang (1-9) and Ang(1-7) ([Figure 1](#fig1){ref-type="fig"}, panel B). Importantly, Ang(1-7) counteracts the AT~1~R-mediated aforementioned detrimental effects induced by Ang II in the lungs. Accordingly, genetic deletion of ACE-2 worsens experimental ARDS ([@bib21]), while Ang(1-7) and ACEIs or ARBs administration improve it ([@bib14]; [@bib34]). Thus, blunting the ACE-1--Ang II--AT~1~R axis while enhancing the ACE-1--Ang II--AT~2~R, the ACE-2--Ang(1-7)-AT~2~R or the ACE-2--Ang(1-7)--MasR receptor axes ([Figure 1](#fig1){ref-type="fig"}, panel B) likely protects from ARDS triggered by infectious pathogens, including coronaviruses ([@bib6]; [@bib14]; [@bib18]; [@bib26]).

Do ACEIs or ARBs facilitate SARS-CoV-2 pathogenicity and the clinical course of COVID-19? {#s4}
=========================================================================================

After ACE-2 was identified as the SARS-CoV-2 receptor ([@bib13]; [@bib38]), unexpectedly, and almost immediately, it was contended that treatment with ACEIs and ARBs would be harmful for COVID-19 patients. This hypothesis was quickly spread in the public, causing confusion and fear in patients taking these drugs, who started asking themselves, and their doctors if they should discontinue these medications and replace them with of antihypertensive drugs of other classes.

The confusion caused in the medical community and the public was due to the publication of two commentaries containing simple hypotheses in the absence of supporting evidence. In one commentary ACE-2 was suggested to be secreted at higher amounts in patients with cardiovascular disease than in healthy individuals, and in another, it was also stated that '*ACE-2 levels can be increased by the use of ACEIs*' ([@bib41]), albeit no evidence of this occurring in the lungs exists. These hypothetical phenomena were put forward to suggest and enhanced susceptibility to SARS-CoV-2 infection, and thus to warn patients about taking these drugs.

Correspondence to the Lancet Respiratory Medicine suggested that patients with cardiac diseases, as hypertension and/or diabetes treated with *'ACE-2-increasing drugs'* would be at higher risk for severe SARS-CoV-2 infection, because treatment with ACEIs and ARBs would raise ACE-2 ([@bib8]). To support their contention, the authors quoted a review article that however did not report such evidence ([@bib23]). To the contrary, a search of the literature revealed that no data that would support such notion exist. In fact, evidence of ACE-2 upregulation applies to the heart, likely as a compensatory phenomenon to underlying conditions, for example myocardial infarction ([@bib2]; [@bib16]; [@bib27]), rather than to the drug treatment per se.

Moreover, in neither commentary the authors considered the fact that increased plasma levels of ACE-2 (generated by delivering soluble forms of rhACE-2 and/or increasing shedding of ACE-2 from the cell membrane) can capture the S protein of SARS-CoV-2 (and SARS-CoV) in plasma, thus preventing the virus from binding to lung cells, two strategies that have been suggested to protect against SARS-CoV-2 infection of the lungs ([@bib20]; [@bib40]) ([Figure 1](#fig1){ref-type="fig"}, panel A).

Nonetheless, the publication of simple hypotheses unsubstantiated by any data spread so fast in public and news portals that scientific societies, including the European Society of Hypertension (ESH), the Italian Society of Cardiology and the Italian Society of Arterial Hypertension were required to release statements to confirm that there is no evidence that ACEIs and ARBs could jeopardize COVID-19 patients, and there is no need to recommend discontinuing treatment. To date, Italy is the country with the highest number of SARS-CoV-2-positive individuals in the European Union and the highest official number of deaths in the world. On March 17^th^, 2020 a joint statement of the presidents of the HFSA/ACC/AHA ([@bib1]), followed by one of the [@bib7], and several experts' opinion articles reported and affirmed that there is no evidence to support discontinuing ACEIs and ARBs ([@bib5]; [@bib9]; [@bib28]), a notion also shared by the Editors of *the New England Journal of Medicine* ([@bib29]).

﻿In our view these neutral recommendations could even be an understatement. In fact, in two large meta-analysis, and a case-control study involving over 21,000 patients in several high-risk categories of patients, including stroke survivors ([@bib30]), in an Asian population ([@bib3]; [@bib25]), and also in patients with Parkinson's disease ([@bib33]), ACEIs were superior to other antihypertensive agents in pneumonia prevention.

The experimental data obtained for the SARS-CoV virus also show that these drugs can be protective rather than harmful, which lead to the proposition of specifically enhancing the protective arm of the renin-angiotensin system as a novel therapeutic strategy for pulmonary diseases ([@bib31]). Moreover, abrupt withdrawal of RAAS inhibitors in high-risk patients, including those who have stage 3 arterial hypertension, heart failure or who had myocardial infarction, may result in clinical instability and adverse health outcomes as pointed out recently ([@bib32]).

ACE inhibitors and ARBs are beneficial in ARDS {#s5}
==============================================

The AT~1~R-mediated detrimental effects of Ang II were demonstrated in several models of ARDS SARS-CoV-induced acute respiratory failure ([@bib14]; [@bib22]; [@bib21]). Moreover, with its vasodilatory, anti-inflammatory, anti-proliferative and antifibrotic effects, activation of the ACE-2--Ang(1-7)--AT~2~R ACE-2--Ang(1-7)--MasR pathways counterbalances the harmful effects of the ACE-1--Ang II--AT~1~R pathway on the lungs. A reduced ratio of ACE-1/ACE-2 has been documented in ARDS; furthermore, experimentally ARDS and lung fibrosis can be prevented by administration of Ang(1-7) ([@bib4]), or ARBs ([@bib34]), indicating that ACE-2 activation limits pulmonary disease progression. This implies not only that ACEIs and ARBs are unlikely to be detrimental in COVID-19 patients, but that they likely will be protective. Whether the same applies to drugs that block the mineralocorticoid receptor and antagonize aldosterone, another downstream mediator in the ACE-1--Ang II--AT~1~R pathway, remains unknown.

In endothelial and lung type 2 alveolar epithelial cells, SARS-CoV-2 downregulates ACE-2 ([@bib21]) and thereby the ACE-2--Ang(1-7)--MasR pathway ([@bib15]). This would also suggest that ACEIs and ARBs can be beneficial by blunting the ACE-1--Ang II--AT~1~R pathway and counterbalancing the down-regulation of ACE-2 ([Figure 1](#fig1){ref-type="fig"}). Administration of recombinant soluble human ACE-2 (rhACE-2) to capture SARS-COV-2 in the bloodstream may prevent its binding to lung cells, and enhance ACE-2 activity in lung tissue ([Figure 1](#fig1){ref-type="fig"}, panel A), which could be beneficial for COVID-19 patients with ARDS, possibly even at a late stage of the infection for patients in intensive care requiring assisted ventilation. Along these lines, in 2017 a pilot trial in patients with ARDS conducted in ten U.S intensive care units supports the value of this strategy in that rhACE-2 increased levels of both Ang(1-7) and alveolar surfactant protein D levels, and tended to lower the concentrations of the proinflammatory cytokine interleukin-6 ([@bib19]).

![Mechanisms of COVID-19 by which the SARS-COV-2 virus infects the lower airway cells and modalities to increase circulating soluble ACE-2 for therapeutic use.\
(**A**) By binding to endothelial and type 2 alveolar epithelial cells that express ACE-2 at high levels, the virus activates proteases, such as TMPRSS2. This allows fusion with the virus' envelope to the cell membrane facilitating the virus to enter and infect the cell. Of note, type 2 alveolar epithelial cells are well equipped with a molecular machinery that allows rapid replication of the viruses thus enhancing pulmonary spreading of the infection. Once infected by SARS-COV-2 the lung cells downregulates expression of ACE-2. Therefore, the lungs remain exposed to, and are unprotected from, the detrimental actions of angiotensin II acting via the AT~1~R. Increasing circulating soluble ACE-2 levels represents a potential new therapeutic principle to treat SARS-CoV-2 infection. This can be achieved using different strategies: either by increasing ADAM-17-dependent shedding of ACE-2 facilitating its removal from tissue (Strategy A) or by intravenous administration of recombinant soluble ACE-2 to capture and thereby inactivate SARS-CoV-2 in plasma and preventing it from entering the cell (Strategy B). (**B**). The renin-angiotensin system in the pathophysiology of SARS-CoV-2-associated ARDS. Ang II - via the AT~1~R - promotes inflammation, vasoconstriction, cell proliferation, and vascular leakage and eventually, pulmonary fibrosis. These effects are counteracted by ACE-2 dependent formation of Ang(1-7) activating the AT~2~R, MasR, and MrgD and formation of Ang(1-9) activating the AT~2~R. The potential beneficial effects of ACEIs and ARBs entail rescuing the downregulated ACE-1--Ang II--AT~2~R and the ACE-2--Ang(1-7)--AT~2~R and ACE-2--Ang(1-7)--MasR pathways in the lungs and capturing the virus in the circulation, thus impeding its binding to the lung cells and preventing damage to the lungs. Abbreviations used: ACE-1, angiotensin converting enzyme-1; ACE-2, angiotensin converting enzyme-2; ACEIs, angiotensin converting enyzme inhibitors; ARBs, angiotensin AT~1~ receptor blockers; AT~1~R, angiotensin II type 1 receptor; AT~2~R, angiotensin II type 2 receptor; NEP, neutral endopeptidase/Neprilysin; MrgprD, G-protein-coupled receptor MrgD; rhACE-2, recombinant soluble human ACE-2; soluble RBD of ACE-2, soluble receptor-binding domain of ACE-2; TMPRSS2, Transmembrane serine protease-2.](elife-57278-fig1){#fig1}

Conclusions and perspectives {#s6}
============================

In summary, a disbalance between the ACE-1-Ang II-AT~1~R and the ACE-1--Ang II--AT~2~R and the ACE-2-Ang(1-7)-AT~2~R and the ACE-2--Ang(1-7)--MasR pathways contributes to the pathogenesis of ARDS and acute lung failure which likely is also relevant for COVID-19 patients. Therefore, it seems reasonable to conclude that rebalancing the system by blunting the deleterious effects of Ang II using ACEIs and ARBs while enhancing the ACE-2 axis is a valuable strategy to minimize the harmful effects of SARS-CoV-2 on the lungs. In the majority of patients with cardiovascular diseases, mainly hypertension, heart failure, or ischemic heart disease, who are on ACEis or ARBs and at risk of becoming infected, or have been infected by SARS-CoV-2 but do not need mechanical ventilation, there is no evidence for deleterious effects of ACEI or ARBs. In fact, discontinuing these life-saving medications potentially can be harmful.
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